Pozelimab

Definition

A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.

Also known as POZELIMAB, REGN 3918, REGN-3918, REGN3918, WHO 10945 — per NCIT

Also identified as

• ATC L04AJ11 per RXNORM
• NCIT NCIT:C166423 per NCIT
• UNII 0JJ21K6L2I per RXNORM

Indications